Inflammation is currently considered a prime target for stroke therapies, and several preclinical studies have demonstrated the effectiveness of drugs targeting inflammatory factors, such as TNF, interleukin (IL)-6, and IL-10 [41]. The gene discussed is TNF; the disease is Stroke.